Latest Insider Transactions at Cytokinetics Inc (CYTK)
This section provides a real-time view of insider transactions for Cytokinetics Inc (CYTK). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CYTOKINETICS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CYTOKINETICS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 04
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.69%
|
$96,000
$48.06 P/Share
|
|
Feb 04
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+1.67%
|
$20,000
$10.6 P/Share
|
|
Jan 21
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.69%
|
$90,000
$45.92 P/Share
|
|
Jan 21
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+1.67%
|
$20,000
$10.6 P/Share
|
|
Jan 07
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.69%
|
$98,000
$49.32 P/Share
|
|
Jan 07
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+1.67%
|
$20,000
$10.6 P/Share
|
|
Jan 02
2025
|
Edward M. Md Kaye Director |
BUY
Grant, award, or other acquisition
|
Direct |
255
+0.98%
|
$12,240
$48.93 P/Share
|
|
Jan 02
2025
|
Robert Arthur Harrington Director |
BUY
Grant, award, or other acquisition
|
Direct |
255
+1.57%
|
$12,240
$48.93 P/Share
|
|
Jan 02
2025
|
John T Henderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
434
+0.88%
|
$20,832
$48.93 P/Share
|
|
Jan 02
2025
|
Wendall Wierenga Director |
BUY
Grant, award, or other acquisition
|
Direct |
127
+0.51%
|
$6,096
$48.93 P/Share
|
|
Jan 02
2025
|
Nancy Wysenski Director |
BUY
Grant, award, or other acquisition
|
Direct |
127
+0.55%
|
$6,096
$48.93 P/Share
|
|
Dec 16
2024
|
Wendall Wierenga Director |
SELL
Open market or private sale
|
Direct |
742
-2.93%
|
$35,616
$48.61 P/Share
|
|
Dec 16
2024
|
Wendall Wierenga Director |
BUY
Exercise of conversion of derivative security
|
Direct |
742
+2.85%
|
$5,194
$7.37 P/Share
|
|
Dec 11
2024
|
John T Henderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,872
+10.72%
|
$83,104
$7.37 P/Share
|
|
Dec 11
2024
|
John T Henderson Director |
SELL
Open market or private sale
|
Direct |
1,780
-4.42%
|
$89,000
$50.42 P/Share
|
|
Dec 10
2024
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
7,300
-2.99%
|
$365,000
$50.64 P/Share
|
|
Dec 10
2024
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,300
+4.12%
|
$37,100
$7.96 P/Share
|
|
Dec 03
2024
|
Sung Lee EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,607
+9.64%
|
-
|
|
Dec 03
2024
|
Sung Lee EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,536
-3.94%
|
$78,336
$51.51 P/Share
|
|
Dec 03
2024
|
Robert Wong VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,530
+3.99%
|
-
|
|
Dec 03
2024
|
Robert Wong VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
273
-1.5%
|
$13,923
$51.51 P/Share
|
|
Dec 03
2024
|
Fady Ibraham Malik EVP Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+3.3%
|
-
|
|
Dec 03
2024
|
Fady Ibraham Malik EVP Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
2,028
-1.75%
|
$103,428
$51.51 P/Share
|
|
Dec 03
2024
|
Andrew Callos EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,353
+4.47%
|
-
|
|
Dec 03
2024
|
Andrew Callos EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,351
-2.01%
|
$68,901
$51.51 P/Share
|
|
Dec 03
2024
|
Robert I Blum President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
23,059
+2.72%
|
-
|
|
Dec 03
2024
|
Robert I Blum President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,843
-1.43%
|
$297,993
$51.51 P/Share
|
|
Dec 02
2024
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.24%
|
$250,000
$50.76 P/Share
|
|
Dec 02
2024
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.23%
|
$30,000
$6.67 P/Share
|
|
Nov 26
2024
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
7,300
-3.1%
|
$365,000
$50.15 P/Share
|
|
Nov 26
2024
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,300
+4.26%
|
$37,100
$7.96 P/Share
|
|
Nov 25
2024
|
Wendall Wierenga Director |
SELL
Open market or private sale
|
Direct |
742
-2.93%
|
$37,100
$50.0 P/Share
|
|
Nov 25
2024
|
Wendall Wierenga Director |
BUY
Exercise of conversion of derivative security
|
Direct |
742
+2.85%
|
$5,194
$7.37 P/Share
|
|
Nov 18
2024
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.24%
|
$250,000
$50.55 P/Share
|
|
Nov 18
2024
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.23%
|
$30,000
$6.67 P/Share
|
|
Nov 12
2024
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
6,342
-2.66%
|
$367,836
$58.48 P/Share
|
|
Nov 12
2024
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,300
+4.22%
|
$37,100
$7.96 P/Share
|
|
Nov 01
2024
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.24%
|
$255,000
$51.63 P/Share
|
|
Nov 01
2024
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.23%
|
$30,000
$6.67 P/Share
|
|
Oct 30
2024
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
7,300
-3.02%
|
$372,300
$51.92 P/Share
|
|
Oct 30
2024
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,300
+4.16%
|
$37,100
$7.96 P/Share
|
|
Oct 28
2024
|
Wendall Wierenga Director |
SELL
Open market or private sale
|
Direct |
4,452
-15.35%
|
$231,504
$52.25 P/Share
|
|
Oct 28
2024
|
Wendall Wierenga Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,452
+13.3%
|
$31,164
$7.37 P/Share
|
|
Oct 15
2024
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
7,300
-2.97%
|
$394,200
$54.19 P/Share
|
|
Oct 15
2024
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,300
+4.09%
|
$37,100
$7.96 P/Share
|
|
Oct 09
2024
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.24%
|
$275,000
$55.61 P/Share
|
|
Oct 09
2024
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.23%
|
$30,000
$6.67 P/Share
|
|
Oct 01
2024
|
Wendall Wierenga Director |
BUY
Grant, award, or other acquisition
|
Direct |
118
+0.48%
|
$6,136
$52.6 P/Share
|
|
Oct 01
2024
|
Edward M. Md Kaye Director |
BUY
Grant, award, or other acquisition
|
Direct |
237
+0.93%
|
$12,324
$52.6 P/Share
|
|
Oct 01
2024
|
John T Henderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
403
+1.04%
|
$20,956
$52.6 P/Share
|